Stem Cell Therapy: A New Therapeutic Option for Cardiovascular Diseases

Cardiovascular diseases are known as one of major causes of morbidity and mortality worldwide. Despite the many advancement in therapies are associated with cardiovascular diseases, it seems that finding of new therapeutic option is necessary. Cell therapy is one of attractive therapeutic platforms for treatment of a variety of diseases such as cardiovascular diseases. Among of various types of cell therapy, stem cell therapy has been emerged as an effective therapeutic approach in this area. Stem cells divided into multipotent stem cells and pluripotent stem cells. A large number studies indicated that utilization of each of them are associated with a variety of advantages and disadvantages. Multiple lines evidence indicated that stem cell therapy could be used as suitable therapeutic approach for treatment of cardiovascular diseases. Many clinical trials have been performed for assessing efficiency of stem cell therapies in human. However, stem cell therapy are associated with some challenges, but, it seems resolving of them could contribute to using of them as effective therapeutic approach for patients who suffering from cardiovascular diseases. In the current review, we summarized current therapeutic strategies based on stem cells for cardiovascular diseases. J. Cell. Biochem. 119: 95–104, 2018. © 2017 Wiley Periodicals, Inc.     

Biglycan Intensifies ALK5–Smad2/3 Signaling by TGF‐β1 and Downregulates Syndecan‐4 in Cultured Vascular Endothelial Cells

Proteoglycans are macromolecules that consist of a core protein and one or more glycosaminoglycan side chains. A small leucine‐rich dermatan sulfate proteoglycan, biglycan, is one of the predominant types of proteoglycans synthesized by vascular endothelial cells; however, the physiological functions of biglycan are not completely understood. In the present study, bovine aortic endothelial cells in culture were transfected with small interfering RNAs for biglycan, and the expression of other proteoglycans was examined. Transforming growth factor‐β₁ signaling was also investigated, because the interaction of biglycan with cytokines has been reported. Biglycan was found to form a complex with either transforming growth factor‐β₁ or the transforming growth factor‐β₁ type I receptor, ALK5, and to intensify the phosphorylation of Smad2/3, resulting in a lower expression of the transmembrane heparan sulfate proteoglycan, syndecan‐4. This is the first report to clarify the function of biglycan as a regulatory molecule of the ALK5–Smad2/3 TGF‐β₁ signaling pathway that mediates the suppression of syndecan‐4 expression in vascular endothelial cells. J. Cell. Biochem. 118: 1087–1096, 2017. © 2016 Wiley Periodicals, Inc.     

Steps in integrin β1-chain glycosylation mediated by TGFβ1 signaling through ras

Ras is activated by transforming growth factor beta (TGFβ) in several cell types, but the biological consequences of this activation are largely unknown. We now show that ras mediates two stages in integrin β1-chain maturation: 1) glycosylation of the 86-kD core peptide, which is a TGFβ1-independent process, and 2) TGFβ1-mediated conversion of the 115-kD β1 integrin precursor into the mature 130-kD form. HD3 colon epithelial cells maintain elevated levels of integrin α2β1 heterodimers, strong binding to collagen I, and autocrine regulation by TGFβ1, which converts β1 integrin into the mature cell surface form. Each of three HD3 cell clones that stably express dominant negative ras (N17ras) exhibited abnormal glycosylation of the integrin β1-chain, decreased cell surface expression of the mature integrin β1, and impaired binding to collagen and laminin. Autocrine levels of TGFβ were not altered by expression of N17ras. The aberrant glycosylation of the integrin β1-chain was reversed by antisense oligonucleotides specific to the DNA sequence encoding the rasS17N mutation. Glycosylation of the 86-kD core peptide was delayed in the N17ras transfectants, but was not altered by either the addition of TGFβ1 or inhibition of autocrine TGFβ1. In contrast, conversion of the partially glycosylated β1 integrin precursor into the mature 130-kD isoform was accelerated by exogenous TGFβ1 and blocked by neutralizing antibody to autocrine TGFβ1 in control cell lines. Neither effect was seen in the N17ras transfectants, indicating that TGFβ1 modulates integrin β1-chain maturation by activating ras proteins. Cell fractionation studies demonstrated that this conversion takes place within the Golgi. J. Cell. Physiol. 181:33–44, 1999. © 1999 Wiley-Liss, Inc.